4 analysts have shared their evaluations of Personalis (NASDAQ:PSNL) during the recent three months, expressing a mix of bullish and bearish perspectives.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $3.62, a high estimate of $4.00, and a low estimate of $3.50. Marking an increase of 3.43%, the current average surpasses the previous average price target of $3.50.

Interpreting Analyst Ratings: A Closer Look

The perception of Personalis by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Personalis's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Personalis analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About Personalis

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

A Deep Dive into Personalis's Financials

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Revenue Growth: Over the 3 months period, Personalis showcased positive performance, achieving a revenue growth rate of 3.53% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Personalis's net margin excels beyond industry benchmarks, reaching -66.42%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Personalis's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -10.37%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Personalis's ROA stands out, surpassing industry averages. With an impressive ROA of -6.17%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: Personalis's debt-to-equity ratio is below the industry average at 0.39, reflecting a lower dependency on debt financing and a more conservative financial approach.

The Core of Analyst Ratings: What Every Investor Should Know

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.